Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024-Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
The New Report “Colorectal Cancer Therapeutics Market” published by Premium Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles.
CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.
The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.
Get sample copy of “Colorectal Cancer Therapeutics Market” at: https://www.premiummarketinsights.com/sample/GBI00004582
– -The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
-How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth-
-What effect will patent expirations of currently branded therapies have on market value-
-The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
-What are the common targets and mechanisms of action of pipeline therapies-
-Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients-
-What implications will the increased focus on targeted therapies have on the future of CRC treatment-
-Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
-How have the late-stage therapies performed in clinical trials-
-How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset-
-The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
-How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets-
-How could changes in risk factors such as population age, obesity and lifestyle influence the market-
-Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
-How do deal frequency and value compare between target families and molecule types-
-What were the terms and conditions of key licensing deals-
Have any query? Enquire about report at: https://www.premiummarketinsights.com/discount/GBI00004582
Fundamentals of Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Colorectal Cancer Therapeutics Market Size
2.2 Colorectal Cancer Therapeutics Growth Trends by Regions
2.3 Industry Trends
3 Market Share by Key Players
3.1 Colorectal Cancer Therapeutics Market Size by Manufacturers
3.2 Colorectal Cancer Therapeutics Key Players Head office and Area Served
3.3 Key Players Colorectal Cancer Therapeutics Product/Solution/Service
3.4 Date of Enter into Colorectal Cancer Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Colorectal Cancer Therapeutics Sales by Product
4.2 Global Colorectal Cancer Therapeutics Revenue by Product
4.3 Colorectal Cancer Therapeutics Price by Product
5 Breakdown Data by End User
5.2 Global Colorectal Cancer Therapeutics Breakdown Data by End User
Get Complete Report at: https://www.premiummarketinsights.com/buy/GBI00004582
Email: [email protected]
Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.